BDBM605817 US11680056, Example 6::US11680056, Example 6A::US11680056, Example 6B::US11680056, Example 6C::US11680056, Example 6D

SMILES Cc1cnc(cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O)-c1ccnc(n1)[C@@](C)(O)C1CC1

InChI Key InChIKey=MFPICHSQTLJIFK-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 605817   

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 31.6nMAssay Description:This study evaluates the inhibitory potency of invention compound on p38/MK2 pathway vs p38/PRAK pathway. More specially the compound concentration (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 1.26E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 25.1nMAssay Description:This study evaluates the inhibitory potency of invention compound on p38/MK2 pathway vs p38/PRAK pathway. More specially the compound concentration (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 5.01nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 1.00E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 3.16E+3nMAssay Description:This study evaluates the inhibitory potency of invention compound on p38/MK2 pathway vs p38/PRAK pathway. More specially the compound concentration (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 3.16E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 2.51E+3nMAssay Description:This study evaluates the inhibitory potency of invention compound on p38/MK2 pathway vs p38/PRAK pathway. More specially the compound concentration (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 2 [46-400](Human)
Xinthera

US Patent
LigandPNGBDBM605817(US11680056, Example 6 | US11680056, Example 6B | U...)
Affinity DataIC50: 3.16E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/25/2023
Entry Details
Go to US Patent